AstraZeneca and MSD’s Lynparza (Olaparib) Receives the CHMP’s Positive Opinion as 1L Maintenance Treatment for HRD-Positive Advanced Ovarian Cancer

 AstraZeneca and MSD’s Lynparza (Olaparib) Receives the CHMP’s Positive Opinion as 1L Maintenance Treatment for HRD-Positive Advanced Ovarian Cancer

AstraZeneca and MSD’s Lynparza (Olaparib) Receives the CHMP’s Positive Opinion as 1L Maintenance Treatment for HRD-Positive Advanced Ovarian Cancer

Shots:

  • The CHMP has recommended the approval of Lynparza + bevacizumab for the 1L maintenance treatment of patients with HRD+ advanced ovarian cancer. The positive opinion is based on a biomarker subgroup analysis of P-III PAOLA-1 study
  • The P-III PAOLA-1 study involves assessing of Lynparza + bevacizumab vs bevacizumab as monothx. for newly diagnosed advanced FIGO Stage III-IV high-grade serous/ endometroid ovarian, fallopian tube, or peritoneal cancer patients who had a complete or partial response to 1L treatment with Pt. based CT and bevacizumab
  • The study resulted in 67% reduction the risk of disease progression or death, improved PFS (37.2 vs 17.7 mos.). Further results of PAOLA-1 trial demonstrated improvement in the time to second disease progression, PFS2 (50.3 vs 35.3 mos.), presented at ESMO 2020

Click here ­to­ read full press release/ article | Ref: AstraZeneca | Image: StraitTimes

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post